Most G6PD deficiency patients show no symptoms until exposure to external triggers that could lead to moderate and severe symptoms, such as acute or chronic hemolytic anemia, favism, neonatal jaundice, and hyperbilirubinemia [4]
Novo Nordisk launched an oral version of Wegovy in the United States in January 2026, while Eli Lilly has secured approval for its oral GLP-1 therapy orforglipron
There was one death attributed to semaglutide in this dataset
At the same time, responsible futuring ensures that envisioned solutions and future developments integrate social and ethical dimensions, promoting inclusive and sustainable urban spaces
Emerging evidence suggests that variations in gut microbiota composition significantly influence the efficiency and outcome of glucoraphanin metabolism, while sulforaphane itself may reciprocally modulate gut microbiota composition and functionality